Multiple Evanescent White Dot Syndrome Following Medigen Vaccine Biologics Corporation COVID-19 Vaccination

Lin, Keng-Sheng; Hsieh, Ming-Kai

doi:10.1080/09273948.2022.2062388

Cited by 11 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(Fig. 1 ) Thirty-two were case reports (71.11%) [ 12 , 18 , 20 , 24 – 26 , 35 – 64 ] and 13 were case series (31.11%). [ 17 , 65 – 76 ] Sixty-four patients were included.…”

Section: Resultsmentioning

confidence: 99%

“…VF: paracentral scotoma with mean deviation of 5.57 db in the OD. The paracentral scotoma was prominent in the inferior nasal area in the OD, which was corresponding to her flashing lights symptom and the white dots lesion in the fundus imaging MVC COVID-19 Vaccination 1 2 Mild fatigue, and the highest recorded body temperature was 37.5° Celsius Da Silva et al [ 24 ] Detrick et al [ 73 ] Suggestive of AMN in both cases Unremarkable for both cases Case 1: Blood tests: showed reduced neutrophil count and very mild thrombo- cytopenia (141 000/μL – reference values 150–450 000/μL) Vaxzervria 1 NA NA Detrick et al [ 73 ] Diafas Et al [ 48 ] Hyperreflectivity and disruption to the outer retinal layers from outer plexiform layer (OPL) to the RPE in both foveae correlating well-circumscribed lesions with early dense hypofluoroescence, followed by late hyperfluoroescence Serological investigations and a chest X-ray ruled out infectious, autoimmune, and inflammatory aetiologias while MRI of the brain ruled out central nervous system (CNS) vasculitis Pfizer-BioNTech-BioNTech Manufacturing 2 NA NA Diafas Et al [ 48 ] Dumitru [ 49 ] Multifocal highly reflective lesions at the junction of the outer plexiform layer (OPL) and outer nuclear layers (ONL), with disruption of the underlying ellipsoid and interdigitation zones (EZ/IZ) consistent with AMN Subtle macular hypoautofluorescence was observed on the left side Initial laboratory work- up revealed inflammatory syndrome with high-level of C-Reactive protein (54 mg/L) and a leukopenia (2.6 G/L) Platelets were normal (278 G/L). Coagulation screening tests, including prothrombin time and activated partial thromboplastin time were normal.…”

Section: Resultsmentioning

confidence: 99%

“…(Fig. 1) Thirtytwo were case reports (71.11%) [12,18,20,[24][25][26] and 13 were case series (31.11%). [17,[65][66][67][68][69][70][71][72][73][74][75][76] Sixty-four patients were included.…”

Section: Resultsmentioning

confidence: 99%

“…[17,[20][21][22][23] Furthermore, Medigen Vaccine Biologics Corporation (MVC) and Sinovac have been reported to cause MEWDS. [24,25] Oxford-AstraZeneca, Sinopharm, and Johnson & Johnson also were reported to cause AMN [26][27][28][29].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The characteristics of white dot syndromes following COVID-19 Vaccines: a systematic review

Abu Serhan,

Abu Suilik,

Hassan

et al. 2024

Int Ophthalmol

View full text Add to dashboard Cite

Purpose To review all studies reporting the onset of white dot syndromes following COVID-19 vaccines. Methods Our protocol was registered prospectively on PROSPERO [registration number: CRD42023426012]. We searched five different databases including PubMed, Scopus, Web of Science, Google Scholar, and Science Direct up to May 2023. All the studies that reported the occurrence of white dot syndrome following COVID-19 vaccines were included. All statistical tests were conducted with a 95% confidence interval and a 5% error margin. A p value of less than 0.05 was considered statistically significant. The methodological quality of included studies was performed using the IHE Quality Appraisal Checklist for Case Series studies and JBI Critical Appraisal Checklist for Case Reports. Results Fifty studies involving seventy-one subjects were included. Multiple evanescent white dot syndrome (MEWDS) was the most common disease (n = 25, 35.2% %), followed by acute macular neuroretinopathy (AMN) (n = 22, 31.0%) and acute posterior multifocal placoid pigment epitheliopathy (APMPPE) (n = 4, 5.6%). They were mostly unilateral (n = 50, 70.4%). The presenting symptoms were blurred vision (n = 26, 36.6%), paracentral scotoma (n = 19, 26.8%), visual field disturbance, and photopsia (n = 7, 9.9%). The mean duration for follow-up was 10.15 ± 14.04 weeks. Nineteen subjects (29.69%) received steroids with improvement reported in 68.4%. Eleven subjects (17.19%) were managed by observation only with reported full recovery and improvement. Conclusion White dot syndromes are very rare entities. Our findings highlight a possible association between COVID-19 vaccines and the occurrence of white dot syndromes. However, larger studies with good quality should be implemented to confirm these findings.

show abstract

“…(Fig. 1 ) Thirty-two were case reports (71.11%) [ 12 , 18 , 20 , 24 – 26 , 35 – 64 ] and 13 were case series (31.11%). [ 17 , 65 – 76 ] Sixty-four patients were included.…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The characteristics of white dot syndromes following COVID-19 Vaccines: a systematic review

Abu Serhan,

Abu Suilik,

Hassan

et al. 2024

Int Ophthalmol

View full text Add to dashboard Cite

show abstract

“…One month after the second injection, the neutralizing antibody titer in children who received the Moderna vaccine at a 50 μg level was 1610, compared to 1300 at the 100 μg level in young adults [ 69 ]. The efficacy was 88.0% against SARS-CoV-2 14 days or more after the first injection when B.1.617.2 (delta) was the dominant circulating variant [ 66 ]. The results suggest that two 50 μg doses of Moderna vaccine were safe and effective in inducing immune responses and preventing children aged 6 to 11 years from contracting COVID-19 [ 69 ].…”

Section: Recent Advancements In Covid-19 Vaccinesmentioning

confidence: 99%

Challenges and Recent Advancements in COVID-19 Vaccines

2023

View full text Add to dashboard Cite

Vaccination is the most effective method for the prevention of COVID-19 caused by SARS-CoV-2, which is still a global epidemic. However, the evolution of SARS-CoV-2 is so rapid that various variants, including the Alpha, Beta, Gamma, Delta, and Omicron variants, have emerged, lowering the protection rate of vaccines and even resulting in breakthrough infections. Additionally, some rare but severe adverse reactions induced by COVID-19 vaccines may raise safety concerns and hinder vaccine promotion; however, clinical studies have shown that the benefits of vaccination outweigh the risks caused by adverse reactions. Current vaccines approved with emergency use authorization (EUA) were originally adaptive for adults only, and infants, children, and adolescents are not included. New-generation vaccines are needed to overcome the challenges of limited adaptive age population, breakthrough infection (mainly due to virus variant emergencies), and critical adverse reactions. Fortunately, some advances in COVID-19 vaccines have been obtained regarding enlarged adaptive populations for clinical applications, such as the Pfizer/BioNTech vaccine and the Moderna vaccine. In this article, we provide a review on the challenges and recent advancements in COVID-19 vaccines. The development of next-generation COVID-19 vaccines should lay emphasis on the expansion of adaptive age populations in all individuals, the induction of immune responses to viral variants, the avoidance or alleviation of rare but potentially critical adverse reactions, and the discovery of subunit vaccines with adjuvants encapsulated in nanoparticles.

show abstract

Tozinameran

2023

Reactions Weekly

View full text Add to dashboard Cite

Multiple Evanescent White Dot Syndrome Following Medigen Vaccine Biologics Corporation COVID-19 Vaccination

Cited by 11 publications

References 15 publications

The characteristics of white dot syndromes following COVID-19 Vaccines: a systematic review

The characteristics of white dot syndromes following COVID-19 Vaccines: a systematic review

Challenges and Recent Advancements in COVID-19 Vaccines

Tozinameran

Contact Info

Product

Resources

About